Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
All content for The Lancet in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
Rasha Al-Lamee and Shayna Chotai on ESC 2024 highlights
The Lancet in conversation with
40 minutes
1 year ago
Rasha Al-Lamee and Shayna Chotai on ESC 2024 highlights
Rasha Al-Lamee and Shayna Chotai join Chloe Wilson of The Lancet to discuss ESC Congress 2024 highlights.The papers featured on this podcast are:1) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01733-1/fulltext2) https://www.nejm.org/doi/abs/10.1056/NEJMoa24091343) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01454-5/abstract4) https://www.nejm.org/doi/abs/10.1056/NEJMoa23143285) https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Elevat...
The Lancet in conversation with
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
